{"slug":"retatrutide-tendon","verification":{"valid":true,"entries":2,"head":"ee38ba5fe8df3983c013d67336f7528e44978c8553965675db4bc137b13f77e9"},"energy":{"passes":2,"tokens_in":14452,"tokens_out":2835,"tokens_total":17287,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"ee38ba5fe8df3983c013d67336f7528e44978c8553965675db4bc137b13f77e9"},"provenance":[{"ts":"2026-06-30T00:50:04.929Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Tendon\nSlug: retatrutide-tendon\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimu","response":"{\n  \"slug\": \"retatrutide-tendon\",\n  \"title\": \"Retatrutide for Tendon Load: Evidence on Weight Reduction and Mechanical Stress\",\n  \"body\": \"## What's breaking down\\n\\nTendons transmit force from muscle to bone. Excess body weight increases tensile and compressive forces across tendon insertions, especially in the Achilles, patellar, and elbow tendons. Obesity correlates with thicker but structurally altered tendons and higher rates of degenerative tendinopathy. Chronic low-grade inflammation from adiposity adds another layer that can impair tendon matrix repair. Mechanical overload outruns adaptive repair capacity, allowing micro-damage to accumulate into symptomatic pathology.\\n\\n## Why Retatrutide might help you\\n\\n1. **What keeps failing:** Excess body weight multiplies force through tendons during daily movement and exercise.\\n2. **What Retatrutide is studied to do:** It activates GLP-1, GIP, and glucagon receptors to drive substantial weight loss.\\n3. **Therefore for you:** If mechanical overload from body weight contributes to your tendon issue, reduced mass lowers the daily load the tendon must withstand, giving repair processes a better chance to keep pace.\\n\\nRetatrutide does not act directly on tendon cells or collagen synthesis. Any benefit flows through the metabolic-load pathway.\\n\\n## How these fit together\\n\\nSingle-compound focus. Retatrutide targets the metabolic-load layer. Other interventions would be needed for direct tendon matrix repair, inflammation modulation, or load management through strengthening.\\n\\n## What the evidence actually shows\\n\\nHuman trials (phase 2, NEJM 2023): 338 adults with obesity received retatrutide or placebo for 48 weeks. The 12 mg group lost a mean 24.2% body weight versus 2.1% on placebo. Over 80% achieved ≥15% loss at higher doses. Phase 3 TRIUMPH-1 data (2026 press release): 12 mg produced mean 28.3% loss (70.3 lb) over 80 weeks, with 45% reaching ≥30% loss. These are human trial results.\\n\\nNo human trials test ret","tokens_in":14452,"tokens_out":2835,"cost":0,"prev":"genesis","hash":"ee7bcb1540e358e2c3807a1d2a1c546be3c33a331bc1e50dec7fa08d2e8a60f7"},{"ts":"2026-07-17T02:41:21.821Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-tendon","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ee7bcb1540e358e2c3807a1d2a1c546be3c33a331bc1e50dec7fa08d2e8a60f7","hash":"ee38ba5fe8df3983c013d67336f7528e44978c8553965675db4bc137b13f77e9"}]}